BioMarin: BioMarin Pharma's phase 3 PEGASUS trial evaluating Palynziq in adolescents with phenylketonuria meets primary efficacy endpoint
BioMarin Pharmaceutical Inc. announced that the phase 3 PEGASUS trial evaluating Palynziq (pegvaliase─pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in
Read full article »
BioMarin is a California-based biotechnology company that researches and develops transformative therapies for the treatment of genetic diseases.
Read more